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ABSTRACT
G-protein subunit a-11 (Ga11) couples the calcium-sensing receptor (CaSR) to phospholipase C (PLC)-mediated intracellular calcium
(Ca2þi) and mitogen-activated protein kinase (MAPK) signaling, which in the parathyroid glands and kidneys regulates parathyroid
hormone release and urinary calcium excretion, respectively. Heterozygous germline loss-of-function Ga11 mutations cause familial
hypocalciuric hypercalcemia type 2 (FHH2), for which effective therapies are currently not available. Here, we report a novel
heterozygous Ga11 germline mutation, Phe220Ser, which was associated with hypercalcemia in a family with FHH2. Homology
modeling showed the wild-type (WT) Phe220 nonpolar residue to form part of a cluster of hydrophobic residues within a highly
conserved cleft region of Ga11, which binds to and activates PLC; and predicted that substitution of Phe220 with the mutant Ser220
polar hydrophilic residue would disrupt PLC-mediated signaling. In vitro studies involving transient transfection of WT and mutant
Ga11 proteins into HEK293 cells, which express the CaSR, showed the mutant Ser220 Ga11 protein to impair CaSR-mediated Ca
2þ
i
and extracellular signal-regulated kinase 1/2 (ERK) MAPK signaling, consistent with diminished activation of PLC. Furthermore,
engineered mutagenesis studies demonstrated that loss of hydrophobicity within the Ga11 cleft region also impaired signaling by
PLC. The loss-of-function associated with the Ser220 Ga11 mutant was rectiﬁed by treatment of cells with cinacalcet, which is a
CaSR-positive allosteric modulator. Furthermore, in vivo administration of cinacalcet to the proband harboring the Phe220Ser Ga11
mutation, normalized serum ionized calcium concentrations. Thus, our studies, which report a novel Ga11 germline mutation
(Phe220Ser) in a family with FHH2, reveal the importance of the Ga11 hydrophobic cleft region for CaSR-mediated activation of PLC,
and show that allosteric CaSR modulation can rectify the loss-of-function Phe220Ser mutation and ameliorate the hypercalcemia
associated with FHH2. © 2017 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
KEY WORDS: PARATHYROID-RELATED DISORDERS; DISORDERS OF CALCIUM/PHOSPHATE METABOLISM; THERAPEUTICS; CELL/TISSUE
SIGNALING; ENDOCRINE PATHWAYS
Introduction
G-protein subunit alpha-11 (Ga11) is a major downstreamsignaling partner of the cell-surface calcium-sensing
receptor (CaSR), which is a family C G-protein coupled receptor
(GPCR) that plays a pivotal role in the parathyroid and renal
regulation of extracellular calcium (Ca2þe) concentrations.
(1)
Ga11 belongs to the Gq/11 class of G-proteins that enhance
phospholipase C (PLC) activity, thereby leading to formation of:
inositol 1,4,5-trisphosphate (IP3), which induces rapid increases
in intracellular Ca2þ (Ca2þi) concentrations; and enhances
diacylglycerol (DAG) formation, which in turn activates protein
kinase C and the mitogen-activated protein kinase (MAPK)
signaling cascade.(2,3) These signal transduction events allow
the CaSR to respond to small ﬂuctuations in the prevailing
Ca2þe concentrations ([Ca
2þ]e) and to induce alterations in
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parathyroid hormone (PTH) secretion and urinary calcium
excretion.(4)
The identiﬁcation of germline heterozygous mutations of Ga11,
which is encoded by theGNA11 gene on chromosome 19p13.3, that
result in familial hypocalciuric hypercalcemia (FHH) has demon-
strated the importance of this G-protein subunit in Ca2þe
homeostasis.(5) FHH is an autosomal dominant disorder character-
ized by lifelong elevations of serum calcium concentrations in
association with normal or mildly raised serum PTH concentrations
and low urinary calcium excretion (calcium-to-creatinine clearance
ratio <0.01).(4) FHH comprises three genetically distinct conditions,
designated as FHH types 1 to 3. FHH1 (OMIM #145980) is caused by
loss-of-function CaSR mutations.(1) FHH2 (OMIM #145981) is caused
by loss-of-function Ga11 mutations; to date, three FHH2-associated
mutations havebeen reported, comprising twomissensemutations,
Thr54Met and Leu135Gln, and an in-frame isoleucine deletion at
codon 200 (Ile200del)(5,6) (Supporting Fig. 1). FHH3 (OMIM #600740)
is caused by loss-of-function mutations of the adaptor protein-2
sigma subunit-1 (AP2S1) gene, encoding AP2s, which is involved in
the clathrin-mediated endocytosis of GPCRs, such as the CaSR.(1)
Positive allosteric modulators of the CaSR, known as
calcimimetics, represent a targeted therapy for patients with
symptomatic FHH. Indeed, cinacalcet, a licensed calcimimetic
drug, has been used to ameliorate symptomatic hypercalcemia
in patients with FHH1 and FHH3.(7–9) However, such effects of
cinacalcet in FHH2 patients have not been reported, although
cinacalcet has been shown in vitro, to rectify signaling
abnormalities associated with FHH2-causing Ga11 mutations.
(10)
Here, we report the effectiveness of cinacalcet in ameliorating
the signaling defects and hypercalcemia due to a previously
unreported FHH2-associated Ga11 mutation, Phe220Ser.
Patients and Methods
Case report
The proband (individual II.1, Fig. 1A) was a 33-year-old male who
presented with headaches, constipation, and pruritus. Biochemi-
cal investigations revealed hypercalcemia, hypophosphatemia,
raised plasma PTH concentrations, and a low urine calcium-to-
creatinine ratio (Table 1). A DXA scan showed normal bone
mineral density values at the spine andhip (Table1).A skinbiopsy,
undertaken to investigate the pruritus, demonstrated folliculitis
(Table 1). His father, and three of his four children, also had
hypercalcemia, constipation, and/or headaches (Table 1). Two of
his affected children had eczema, and the proband’s father had
sustained an osteoporotic vertebral fracture. The familial
hypercalcemia and reduced urinary calcium excretion were
consistentwith FHH; however, CASR orAP2S1mutationswere not
identiﬁed. Informed consent was obtained from individuals and
Fig. 1. Identiﬁcation and structural assessment of a Phe220Ser Ga11 mutation in a family with familial hypocalciuric hypercalcemia type 2. (A) The family
comprised of 5 affected and 3 unaffected members (top). The proband (individual II.1) is indicated by an arrow. A heterozygous T-to-C transition at
nucleotide c.659, predicted to result in a missense substitution of the WT Phe to a mutant (m) Ser at codon 220 of the Ga11 protein, was identiﬁed in the
proband and conﬁrmed to cosegregate with hypercalcemia by Sanger DNA sequence analysis. (B) Multiple protein sequence alignment of residues
comprising the b3-a2 loop, a2-helix, and a2-b4 loop that form switch II (red box) of Ga11 orthologs (top) and Ga-subunit paralogs (bottom). Conserved
residues are shown in gray, and WT (Phe, F) and mutant (Ser, S) residues are shown in red. (C) Structural model showing that Phe220 of Ga11 is part of a
hydrophobic cluster of amino acids (yellow) within switch II and thea3-helix, which stabilize the region in a conformation that facilitates effector binding.
(D) Close-up view of Phe220 residue, within the switch II region of the GTPase domain of Ga11, in complex with phospholipase C-b3 (brown space-ﬁlling
model), with directly interacting residues of the a2 and a3 helices colored blue.
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where appropriate, parents and guardians of children, using
protocols approved by the Research Ethics Committee of the
Helsinki University Hospital.
Mutational analysis
DNA sequence analyses of GNA11 exons 1 to 7 and adjacent
splice sites (NM_002067) was performed using leukocyte DNA
and gene-speciﬁc primers (Sigma-Aldrich, Gillingham, UK), as
reported.(5,6) Polymorphic variants were identiﬁed from public
databases (Supporting Table 1).
Protein sequence alignment and three-dimensional
modeling of Ga11 structure
Protein sequences of Ga11 orthologs were aligned using ClustalO-
mega (European Bioinformatics Institute [EMBL-EBI], Cambridge-
shire, UK; http://www.ebi.ac.uk/Tools/msa/clustalo/).(6) Ga11 three-
dimensional modeling was undertaken using the reported three-
dimensional structures of: Gaq in complex with phospholipase C-b3
(ProteinData Bank accessionno. 3OHM)(11); Gaq in complexwith the
smallmolecule inhibitorYM-254890 (ProteinDataBankaccessionno.
3AH8)(12); and Gaq in complex with the regulator of G-protein
signaling 2 (RGS2) (Protein Data Bank accession no. 4EKC and
4QJ3).(13,14) TheGaq protein, which shares 90% identity at the amino
acid level with Ga11, was used because crystal structures of Ga11 are
not available. Figures were prepared using the PyMOL Molecular
Graphics System, Schrodinger.
Cell culture and transfection
Mutations were introduced into the previously described
pBI-CMV2-GNA11 expression construct by site-directedmutagene-
sisusing theQuikchangeLightningKit (AgilentTechnologies, Santa
Clara, CA, USA) and gene-speciﬁc primers (Sigma-Aldrich). Wild-
type (WT) or mutant pBI-CMV2-GNA11 constructs were transiently
transfected into HEK293 cells stably expressing CaSR (HEK-CaSR)
using Lipofectamine 2000 (Life TechnologiesCarlsbad, CA, USA), as
described.(15,16) The pBI-CMV2-GNA11 bidirectional vector allows
for co-expression of Ga11 and GFP at equivalent levels.
(5) HEK-CaSR
cells were maintained in DMEM-Glutamax media (Gibco, Carlsbad,
CA,USA) thathas a calciumconcentrationof 1.80mM.Thepresence
of mutations was veriﬁed using dideoxynucleotide sequencing
with the BigDye Terminator v3.1 Cycle Sequencing Kit (Life
Technologies) and an automated detection system (ABI3730
Automated capillary sequencer; Applied Biosystems, Carlsbad, CA,
USA).(17) Luciferase reporter constructs (pGL4.30-NFAT, pGL4.33-
SRE) were purchased from Promega. HEK293 cells were used
because suitable parathyroid and renal tubular cells are not
available, and HEK293 cells have been established as a model for
the functional expression of Ga11 proteins.
(5,15,16) HEK-CaSR cells
were cultured in high-glucose DMEM (Invitrogen, Carlsbad, CA,
USA) supplementedwith10%fetalbovine serumand1%Geneticin
at 37°C, 5% CO2.
(5) Successful transfection was conﬁrmed by
visualizing GFP ﬂuorescence using an Eclipse E400 ﬂuorescence
microscope with an epiﬂuorescence ﬁlter, and images were
captured using a DXM1200C digital camera and NIS Elements
software (Nikon, Kingston-Upon-Thames, UK).(5,16) The expression
of Ga11 and CaSR proteinswas conﬁrmedbyWestern blot analyses
using Ga11 (Santa Cruz Biotechnologies), anti-calnexin (Millipore,
Billerica, MA), or anti-CaSR (Abcam, Cambridge, UK) antibodies.
Calnexin, a housekeeping protein, was used as a loading control.
TheWesternblotswerevisualizedusingan Immuno-StarWesternC
kit (BioRad, Hercules, CA, USA) on a BioRad Chemidoc XRSþ
system.(6)
Fluo-4 intracellular calcium assay
Ca2þe-induced Ca
2þ
i responses were measured by Fluo-4
calcium assays adapted from published methods.(18) HEK-CaSR
TABLE 1. Clinical and Biochemical Findings in Available Affected Members of the Family With the Phe220Ser Ga11 Mutation
Individuals
Variable II.1 III.2 III.3 III.4
Sex Male Female Male Female
Age at diagnosis 33 years 7 weeks At birth 18 months
Associated clinical features Headaches, pruritus,
constipationa
Constipation, scoliosis,
headachesb
Premature birth,c eczema,
constipation
Constipation,
eczema
Serum biochemistryd
Ionized calcium (mmol/L) 1.42 1.41 1.46 1.46
Phosphate (mmol/L) 0.50 1.98 1.81 1.62
Alkaline phosphatase (U/L) 77 275 461 243
Magnesium (mmol/L) 0.78 1.00 0.90 0.93
Creatinine (mmol/L) 76 26 78 26
PTH (ng/L) 98 39 100 40
25-hydroxyvitamin D (nmol/L) 49 50 102 122
Thyrotropin (TSH) (mU/L) 2.82 1.83 5.5e 1.53
Urinary calcium excretion 0.09f 0.002 0.001 0.003
aA skin biopsy demonstrated folliculitis with keratin within the widened hair follicle and inﬂammatory cells around the hair follicle. Normal bone
mineral density T-score  –1.0 at lumbar spine and femoral neck.
bIndividual III.2 (Fig. 1) developed headaches from age 10 years.
cIndividual III.3 was born prematurely at gestational age 27þ3 weeks.
dNormal biochemical ranges: ionized calcium, 1.16 to 1.30mmol/L (adults) and 1.16 to 1.39mmol/L (age 1 to 12 months); phosphate, 1.50 to
2.60mmol/L (neonates), 1.50 to 2.50mmol/L (age 1 to 6 months), 1.20 to 1.80mmol/L (age 2 to 12 years), and 0.71 to 1.53mmol/L (adults); alkaline
phosphatase activity, 35 to 105U/L (adults) and 115 to 460U/L (age 15 days to 1 year); magnesium, 0.71 to 0.94mmol/L (adults) and 0.7 to 1.0mmol/L
(age 3months to 17 years); creatinine, 60 to 100mmol/L (adult males) and 10 to 56mmol/L (age 8 days to 2 years); PTH, 8 to 73 ng/L; 25 hydroxyvitamin D,
>50 nmol/L; thyrotropin; 0.5 to 3.6 mU/L (age >14 weeks) and 0.4 to 7 mU/L (age 11 to 14 weeks); calcium-to-creatinine clearance ratio >0.02.
eTSH concentration measured in umbilical cord blood (normal range not available for premature infant cord blood TSH).
fCalcium-to creatinine ratio, normal 0.3–0.7.
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cells were plated in poly-L-lysine treated black-walled 96-well
plates (Corning, Corning, NY, USA), and transiently transfected
with 1000 ng/mL pBI-CMV2-GNA11. Cells were conditioned in
serum-free media (1.8mM Ca2þe) overnight, then incubated in
Ca2þ-free andMg2þ-free Hanks Balanced Salt Solution (HBSS) for
1 hour, followed by loading with Fluo-4 dye, prepared according
to manufacturer’s instructions (Invitrogen). Cells were loaded
for 40min at 37°C, then either a 20% aqueous solution of
2-hydoxypropyl-b-cyclodextrin (vehicle), or 30nM or 100nM
cinacalcet was added. Cells were then incubated for a further
20min at 37°C.(18) Baseline measurements were made and CaCl2
was injected into each well to increase the [Ca2þ]e in a stepwise
manner from 0.5 to 10mM [Ca2þ]e, using an automated system.
Changes in Ca2þi were recorded on a PHERAstar instrument
(BMG Labtech, Aylesbury, UK) at 37°C with an excitation ﬁlter of
485 nm and an emission ﬁlter of 520 nm. The peak mean
ﬂuorescence ratio of the transient response after each individual
stimulus wasmeasured usingMARS data analysis software (BMG
Labtech), and expressed as a normalized response. Nonlinear
regression of concentration-response curves was performed
with GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA)
using the normalized response at each [Ca2þ]e for each separate
experiment for the determination of the EC50 (ie, [Ca
2þ]e
required for 50% of the maximal response). Assays were
performed in four to 12 biological replicates for each of the
expression constructs. Statistical analysis was performed using
the F-test.(5,6)
Luciferase reporter assay
HEK-CaSR cells were seeded in 48-well plates and transiently
transfected with 100 ng/mL pBI-CMV2-GNA11 WT or mutant
proteins, 100 ng/mL luciferase construct (either pGL4-NFAT or
pGL4-SRE) and 10 ng/mL pRL control vector for 48 hours. Cells
were incubated in serum-free media for 12 hours, followed by
treatment of cells for 4 hours with 0.1mM to 10mM CaCl2. Cells
were lysed and assays performed with Dual-Glo luciferase
(Promega, Madison, WI, USA) on a Veritas Luminometer
(Promega), as described.(19) Luciferase:renilla ratios were
expressed as fold-changes relative to responses at basal
CaCl2 concentrations. For studies with cinacalcet (Cambridge
Bioscience, Cambridge, UK), the drug was added to cells, as
described.(10,19) All assays were performed using four biologi-
cal replicates on up to three independent occasions. Statistical
analysis was performed by two-way ANOVA with Tukey’s
multiple-comparisons test using GraphPad Prism 6.
Measurement of ERK phosphorylation
HEK-CaSR cells were seeded in 48-well plates and transfected
with 200 ng/mL WT or mutant Ga11, 48 hours prior to
performance of assays. Transfected cells were incubated in
serum-free media 12 hours prior to treatment of cells with
0.1mM to 10mM CaCl2. Cells were then lysed in Sureﬁre lysis
buffer, and AlphaScreen Sureﬁre ERK assays (PerkinElmer,
Beaconsﬁeld, UK) measuring phosphorylated and total proteins
were performed, as described.(10,19) The ﬂuorescence signal in
both assays was measured using the PHERAstar FS microplate
reader (BMG Labtech).(19) The ratio of phosphorylated ERK
(pERK) to total ERKmeasured at each [Ca2þ]e were normalized to
the mean responses of WT-expressing cells and expressed as a
fold-change of responses obtained at basal (0.1mM) [Ca2þ]e. All
assay conditions were performed in four biological replicates on
up to four independent occasions. Statistical analysis was
performed by two-way ANOVA with Tukey’s multiple-compar-
isons test using GraphPad Prism 6.
Web resources
Predicted effect of the mutation was assessed using Polyphen-2
(http://genetics.bwh.harvard.edu/pph2/)(20) and MutationTast-
ing (http://www.mutationtaster.org/).(21)
Statistics
All studies involved between four and 16 separate transfection
experiments. Statistical analyses for Ca2þi EC50 used the F-test,
(19)
and two-way ANOVAwith Tukey’smultiple-comparisons test was
used for pERK and luciferase reporter assays. Analyses were
undertaken using GraphPad Prism, and a value of p< 0.05 was
considered signiﬁcant.
Results
Identification of a novel Phe220Ser Ga11 mutation in a
family with FHH2
DNA sequence analysis of GNA11 in the proband identiﬁed a
heterozygous T-to-C transition at nucleotide c.659 (Fig. 1A),
resulting in a missense substitution of the WT Phe to a mutant
Ser at residue 220 of the Ga11 protein. Bioinformatic analyses
predicted the Phe220Ser variant to be damaging and likely
disease-causing (Polyphen-2 score¼ 1, MutationTasting score
¼ 0.99). The absence of this DNA sequence abnormality in
>67,200 exomes from the NHLBI-ESP and Exome Aggregation
Consortium cohorts, together with evolutionary conservation of
the Phe220 residue in Ga11 orthologs and Ga-subunit paralogs
(Fig. 1B), also indicated that the Phe220Ser abnormality likely
represents a pathogenic mutation rather than a benign
polymorphic variant.
The Phe220Ser mutation is located in the switch II region
of Ga11 and predicted to impair PLC activation
Homology modeling, using crystal structures of the related Gaq
protein,(11,12,22) revealed the WT Phe220 residue to be located
within the a2-helix of the ﬂexible switch II region of the Ga11
GTPase domain (Fig. 1B, C; Supporting Fig. 1), and to comprise
part of a hydrophobic cluster of amino acids located within a
cleft region formed by switch II and the adjacent a3-helix that
interact with PLC upon G-protein activation (Fig. 1C, D).(11)
Substitution of the nonpolar hydrophobic WT Phe220 residue,
with the mutant polar hydrophilic Ser220 residue is predicted to
disrupt Ga11 function by impairing PLC activation and signaling.
The Ga11 Phe220Ser mutation impairs Ca
2þ
i responses
The Phe220Ser mutation is predicted to diminish PLC activation,
and we therefore assessed its effects on Ca2þi mobilization,
which has previously been shown to be enhanced downstream
of PLC by the Gq/11 proteins.
(23–26) HEK-CaSR cells were
transiently transfected with pBI-CMV2-GNA11 constructs ex-
pressing the WT (Phe220) or mutant (Ser220) Ga11 proteins
(Supporting Fig. 2). The Ca2þi responses of the mutant Ser220
Ga11-expressing HEK-CaSR cells, revealed that a signiﬁcantly
greater [Ca2þ]e was required to achieve half-maximal (EC50)
Ca2þi responses, when compared with WT-expressing cells
(Fig. 2A). Thus, the Ser220 mutant-expressing cells showed a
rightward shift in the concentration-response curve, with a
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signiﬁcantly elevated mean EC50 value (p< 0.001) of 2.93mM
(95% conﬁdence interval [CI], 2.80 to 3.07mM), compared with
2.40mM (95% CI, 2.27 to 2.53mM) for WT-expressing cells. The
Ca2þi responses were also assessed by measurement of nuclear
factor of activated T-cells (NFAT), which is a downstream
mediator of Ca2þi signaling.
(27) NFAT fold-change responses
were determined using a luciferase reporter assay, and these
studies showed that HEK-CaSR cells expressing the Ser220 Ga11
mutant had a signiﬁcantly reduced fold-change response (fold-
change¼ 2.3 0.3) following exposure to 5mM [Ca2þ]e, when
compared with WT cells (fold-change¼ 4.8 0.4, p< 0.001)
(Fig. 2B). These data demonstrated that the Ga11 Phe220Ser
mutation impairs CaSR-mediated Ca2þi responses, consistent
with a loss-of-function associated with FHH2.
The Ga11 Phe220Ser mutation impairs ERK
phosphorylation
The ERK protein represents a major component of the MAPK
signaling cascade, which has previously been shown to be
activated by PLC.(3,28) We assessed the effect of the Ga11
Phe220Ser mutation on ERK phosphorylation by measuring
changes in pERK in response to increases in Ca2þe in WT and
mutant Ser220 Ga11-expressing cells using the AlphaScreen
assay, and also by assessing serum-response element (SRE)-
mediated transcriptional activity, which is regulated by ERK
signaling.(19) The pERK responses of the Ser220 Ga11 mutant
were shown to be signiﬁcantly reduced. Thus, the Ser220 Ga11
mutant led to signiﬁcant reductions in: pERK-to-total ERK ratios
(Ser220 response at 5mM Ca2þe¼ 3.7 0.4 versus Phe220¼ 6.1
 0.3, p< 0.0001) (Fig. 2C); and to SRE reporter fold-changes
(Ser220 fold-change at 5mM Ca2þe¼ 6.5 0.5 versus Phe220
fold-change¼ 11.8 0.7, p< 0.0001) (Fig. 2D). Thus, the
Ga11 Phe220Ser mutation impaired CaSR-mediated ERK
phosphorylation.
Phe220 forms part of a hydrophobic cluster of Ga11
residues required for PLC-mediated signaling
To further determine the mechanistic role of the Phe220 residue
and the importance of residue 220 hydrophobicity for Ga11
function and PLC-mediated signaling (Fig. 1C), we engineered
mutations of Phe220 to Leu and Ala, which are hydrophobic
residues, and to Arg and Glu, which are hydrophilic positively-
charged and negatively-charged residues, respectively, and
studied their effect on Ca2þi and ERK responses following
Fig. 2. Effect of the mutant Ser220 Ga11 on Ca
2þ
i and ERK signaling in HEK-CaSR cells. (A) Ca
2þ
i responses to changes in [Ca
2þ]e of HEK-CaSR cells
expressing WT (Phe220) or mutant (Ser220) Ga11 proteins shown as the mean SE of 4 to 11 transfections. The Ser220 Ga11 mutant caused a rightward
shift in the Ca2þi concentration-response curve with signiﬁcantly increased EC50 value compared to WT cells (p< 0.0001, F-test). (B) [Ca
2þ]e-induced
NFAT reporter responses, which are activated by elevations of Ca2þi, were assessed in HEK-CaSR cells expressingWT or mutant Ga11 proteins. Responses
at each [Ca2þ]e are expressed as a fold-change of basal [Ca
2þ]e responses, and shown as mean SE of 12 transfections. NFAT luciferase reporter activity
increased in all cells in a concentration-dependent manner, and was signiﬁcantly reduced in Ser220 cells compared to WT cells. (C) Ca2þe-induced pERK
responses of cells expressing WT or mutant Ga11 protein, expressed as a ratio to total ERK levels, and shown as mean SE of 8 transfections.
(D) Ca2þe-induced SRE reporter responses of cells expressing WT or mutant Ga11 protein, expressed compared to basal SRE reporter activity, and shown
as mean SE of 8 transfections. The Ser220 Ga11 mutant was associated with signiﬁcantly decreased pERK and SRE reporter responses compared toWT.
p< 0.01 and p< 0.0001, by a 2-way ANOVA with Tukey’s multiple-comparisons test.
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transient expression in HEK-CaSR cells (Fig. 3). The Leu220 and
Ala220 Ga11 mutants did not alter Ca
2þ
i responses (Fig. 3A, B;
Supporting Fig. 3), or ERK activity, as measured using the pERK
AlphaScreen and SRE reporter assays (Fig. 3C, D). In contrast, the
positively-charged Arg220, and negatively-charged Glu220 Ga11
mutants, respectively, enhanced and impaired Ca2þi and ERK
signaling responses in HEK-CaSR cells (Fig. 3, Supporting Fig. 3).
Thus, these ﬁndings demonstrated that a hydrophobic residue
at position 220 is required for signaling via PLC. The
enhancement of CaSR-mediated signaling by the Arg220 Ga11
mutant may be explained by its structural effect on the G11
heterotrimer. Homology modeling, using crystal structures of
the related Gq protein in complex with Gbg,
(12) revealed that the
Arg220 residue faces away from the hydrophobic cluster, into
the region at which Ga and Gbg bind, a hydrophobic region that
is necessary for Ga activation(29) (Supporting Fig. 4). Disruption
of this hydrophobic region has been shown to cause constitutive
activation,(29) and modeling predicts that the Arg220 residue,
which is charged and hydrophilic, disrupts this region,
thus enhancing activation by impairing Gabg association
(Supporting Fig. 4). To investigate the importance of the Ga11
hydrophobic cleft, formed by switch II and the a3-helix (Fig. 1C,
D), for PLC activation, we engineered mutations of three other
hydrophobic residues, Ile217, Val223, and Trp263, within this
region, to either an Ala residue, to retain hydrophobicity, or to a
Glu residue, to lose hydrophobicity, and studied the effects of
these mutants on Ca2þi and ERK responses following their
transient expression in HEK-CaSR cells (Supporting Fig. 5). This
demonstrated that substitution to Ala of only one hydrophobic
residue, Ile217, altered PLC-mediated signaling (Fig. 4A–C;
Supporting Fig. 6). In contrast, substitution of any of the Ile217,
Val223, and Trp263 hydrophobic residues to a Glu residue led to
a signiﬁcant reduction in Ca2þi and ERK responses (Fig. 4D–F,
Supporting Fig. 6). Thus, hydrophobicity of the switch II-a3 cleft
is important for PLC activation.
Cinacalcet rectifies the impaired PLC signaling responses
and hypercalcemia caused by the Phe220Ser Ga11
mutation
To determinewhether cinacalcetmay be an effective therapy for
FHH2, we evaluated the effects of different cinacalcet concen-
trations (0, 30, and 100nM) on the altered PLC signaling
responses due to the Phe220Ser Ga11 mutant. Treatment of
Fig. 3. Effect of Ga11 residue 220 hydrophobicity on PLC-mediated signaling. (A) Histograms showing Ca
2þ
e-induced Ca
2þ
i EC50 values with 95%
conﬁdence intervals (CIs) for cells expressing WT Phe220 or residue 220 mutant (m) Ga11 proteins from 6 to 12 transfections. Statistical analyses were
performed using the F-test. The Arg220 Ga11 mutant reduced the EC50 value, whereas the Glu220 and Ser220 Ga11 mutants elevated the EC50 value.
(B) Ca2þe-induced NFAT reporter responses, which assess Ca
2þ
i signaling, of cells expressingWT or residue 220 mutant Ga11 proteins. Responses at each
[Ca2þ]e are expressed as a fold-change of basal [Ca
2þ]e responses, and shown as mean SE of 4 to 12 transfections. NFAT luciferase reporter activity
increased in all cells in a concentration-dependent manner, however responses were signiﬁcantly elevated in Arg220 Ga11 mutant, and reduced in
Glu220 Ga11 mutant cells, compared to WT cells. (C) Ca
2þ
e-induced pERK responses of cells expressing WT or mutant residue 220 Ga11 proteins,
expressed as a ratio to total ERK levels. The Arg220 mutant was associated with signiﬁcantly increased responses, and the Glu220 and Ser220 mutants
were associated with decreased responses, when compared toWT. Data are shown as mean SE of 4 to 8 independent transfections. (D) Ca2þe-induced
SRE reporter responses of cells expressing WT or mutant (m) residue 220 Ga11 proteins, expressed compared to basal SRE reporter activity. The
engineered Arg220 mutant was associated with signiﬁcantly increased, and the engineered Glu220 and FHH2-associated Ser220 mutants resulted in
decreased responses, when compared to WT. Data are shown as mean SE of 4 to 8 independent transfections. Statistical analyses performed using 2-
way ANOVA with Tukey’s multiple-comparisons test comparing WT with Ga11 mutants Ala220, Arg220, Glu220, and Ser220. p< 0.05, p< 0.01,
p< 0.001, p< 0.0001.
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mutant Ser220 Ga11-expressing HEK-CaSR cells with 30nM
cinacalcet, failed to normalize the impaired Ca2þi and SRE
reporter responses (Fig. 5A–C); however, 100nM cinacalcet,
reduced the EC50 values, and increased NFAT and SRE reporter
activity (Fig. 5A–C), such that these values were not signiﬁcantly
different from untreated WT cells. These in vitro ﬁndings
suggested that higher doses of cinacalcet may be required for
the treatment of patients harboring the Phe220Ser Ga11
mutation. Cinacalcet was administered to the FHH2 proband
as he had symptoms such as headaches, constipation, and
pruritus (Table 1), which may have been caused by the
hypercalcemia. The proband was initially commenced on
30mg/day of oral cinacalcet for 3 months, and in keeping
with the above cellular studies, which showed a lack of efﬁcacy
when using low cinacalcet concentrations, the 30 mg/day dose
failed to normalize his elevated serum calcium concentrations
(Fig. 5D). However, increasing the dose of cinacalcet to 60mg/
day, successfully lowered the serum concentrations of: ionized
calcium from 1.42 to 1.26mmol/L (normal range, 1.16 to
1.30mmol/L) (Fig. 5D); and PTH from 98 to 58 ng/L (normal
Fig. 4. Effect of mutating residues within the Ga11 switch II-a3 hydrophobic cluster on PLC-mediated signaling. (A) Histograms showing Ca
2þ
e-induced
Ca2þi EC50 values with 95% CI for cells expressing WT and alanine (Ala) Ga11 mutants (m) of residues 217, 223, and 263 Ga11 proteins from 4 to 8
independent transfections. Only the Ala217 Ga11mutant increased the EC50 value, when compared toWT cells. Statistical analyseswere performed using
the F-test. (B, C) Ca2þe-induced (B) NFAT and (C) SRE luciferase reporter responses of cells expressingWT or alanine (Ala) Ga11 mutants. Responses at each
[Ca2þ]e are expressed as a fold-change of basal [Ca
2þ]e responses, and shown asmean SE of 4 to 8 transfections. NFAT and SRE reporter responses were
signiﬁcantly reduced in Ala217-expressing cells compared to WT cells. (D) Histograms showing Ca2þe-induced Ca
2þ
i EC50 values with 95% CI for cells
expressing WT and glutamic acid (Glu) Ga11 mutants (m) of residues 217, 223, and 263 from 4 to 8 independent transfections. All Glu Ga11 mutants
increased the EC50 value, when compared to WT cells. Statistical analyses were performed using the F-test. (E, F) Ca
2þ
e-induced (E) NFAT and (F) SRE
luciferase reporter responses of cells expressing WT or glutamic acid (Glu) Ga11 mutants. Responses at each [Ca
2þ]e are expressed as a fold-change of
basal [Ca2þ]e responses, and shown as mean SE of 4 to 8 transfections. NFAT and SRE reporter responses were signiﬁcantly reduced in cells expressing
all 3 glutamic acid mutants compared to WT cells. Statistical analyses for B, C, E, and F were performed using 2-way ANOVA with Tukey’s multiple-
comparisons test comparing WT to mutant 217 (green), 223 (red), and 263 (gray) Ga11 proteins. p< 0.05, p< 0.001, p< 0.0001.
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range, 8 to 73 ng/L). Although the proband became normo-
calcemic on cinacalcet, the pruritus, from which he suffered the
most, did not resolve, and cinacalcet 60mg/day was discon-
tinued after 4 months. His hypercalcemia returned upon
cessation of cinacalcet therapy (Fig. 5D).
Discussion
Our studies have identiﬁed a previously unreported FHH2-
causing heterozygous Ga11 germline loss-of-function mutation
that represents the ﬁrst loss-of-function Ga11 mutation to be
located within the Ga-subunit switch regions. The switch
regions are comprised of three ﬂexible peptide loops, which are
highly conserved among all classes of Ga-subunits, and undergo
substantial conformational changes depending on the guanine
nucleotide-bound state of the Ga subunit.(30) In the GTP-bound
state, these peptide loops switch their conformation to one that
facilitates coupling with downstream effector proteins.(31) The
Phe220Ser mutation is located in the switch II region, which is
predicted to bind and activate PLC,(11) and our in vitro
assessment of Ca2þi and pERK responses in cells expressing
the mutant Ser220 Ga11 demonstrated an impairment of
signaling that is, at least in part, mediated by PLC.(26,32)
Furthermore, our mutagenesis studies showed that Phe220
forms part of a group of hydrophobic residues that are required
for coupling to PLC, and that Phe220 is located in a key region
within this hydrophobic cleft, such that substitution of the
hydrophobic Phe220 residue for a hydrophilic positively (Arg) or
negatively (Glu) charged residue resulted, respectively, in a Ga11
gain-of-function or loss-of-function, thereby indicating that
mutations of Phe220 can either retard or enhance the switch II
conformational changes that occur upon G-protein activation.
These studies have involved a comprehensive investigation of
the effect of FHH2-associated Ga11 mutations on PLC signaling
at both the cytosolic (ie, Ca2þi and pERK) and transcriptional (ie,
NFAT and SRE reporter) level, and demonstrate that all readouts
are affected by FHH2 mutations. The need to measure several
signal outputs is increasingly important as recent studies have
shown that GPCRs can couple to multiple G-proteins to enhance
Fig. 5. Effect of cinacalcet on the loss-of-function and hypercalcemia caused by the Phe220Ser Ga11mutation. (A) Effect of cinacalcet on Ca
2þ
i responses
to changes in [Ca2þ]e of HEK-CaSR cells transfected with WT or Ser220 Ga11 mutant (m). The Ca
2þ
i responses to changes in [Ca
2þ]e are expressed as a
percentage of the maximum normalized responses and shown as the mean SE of 6 to 12 independent transfections. The Ser220 Ga11 mutant led to a
rightward shift in the concentration-response curve. The addition of 30nM cinacalcet, a concentration previously shown to rectify the loss-of-function
associated with the reported Leu135Gln Ga11 FHH2 mutant in vitro,
(10) had no effect on Ser220 responses. However, addition of 100nM cinacalcet
rectiﬁed the rightward shift of the Ser220 Ga11 mutant, such that it was not different to WT responses. (B, C) Histograms showing (B) NFAT and (C) SRE
luciferase reporter activity in response to 5mM Ca2þe in HEK-CaSR cells expressing WT or Ser220 mutant constructs, treated with vehicle or cinacalcet
(CIN). Data are shown as mean SE of 4 independent transfections; 100nM cinacalcet was required to signiﬁcantly increase NFAT and SRE reporter
activity to WT levels. The responses of cells expressing WT or mutant Ga11 proteins were compared using the F-test for A and 2-way ANOVA with Tukey’s
multiple-comparisons test for B and C. p< 0.01, p< 0.001, p< 0.0001. (D) Effect of cinacalcet on the serum ionized calcium concentrations of the
FHH2 proband (individual II.1, Fig. 1A) with the Phe220Ser Ga11mutation. Arrows indicate initiation of oral cinacalcet at 30mg/day (CIN 30), at 60mg/day
(CIN 60), and its discontinuation. Cinacalcet treatment decreased serum concentrations of ionized calcium and PTH from 98ng/L (pretreatment) to
58 ng/L (posttreatment) (normal range, 8 to 73 ng/L). Shaded area indicates normal range.
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their signaling capabilities and respond in diverse tissues.(33,34)
Indeed, this is particularly the case in Ga11 mutant cells, where it
has been hypothesized that other G-proteins, in particular Gaq,
may compensate for some of the functions of Ga11, giving rise to
the milder phenotype observed in FHH2.(5,6) Our studies of the
transcriptional events downstream of CaSR activation indicate
that Ca2þi signaling is more severely impaired than ERK
signaling, as the Ser220 Ga11 mutant cells have more robust
SRE signals than NFAT signals. MAPK signaling is known to occur
downstream of several G-proteins and can be used as a
surrogate to assess multiple G-protein families.(32,35) The
differences observed in Ca2þi signaling compared to ERK
signaling in Ga11 Ser220 mutant cells indicates that Ga11 may
preferentially signal via Ca2þi, or that other G-proteins are able to
compensate for a reduction in Ga11-mediated ERK responses in
FHH2 mutant cells.
The Ga11 protein is considered to be ubiquitously ex-
pressed,(36) thus raising the possibility that germline Ga11
mutations may be associated with non-calciotropic phenotypes.
Indeed, in addition to constipation most of the affected family
members had folliculitis or eczematous skin lesions, which may
potentially represent a non-calciotropic phenotype of FHH2.
This is plausible as somatic activating Ga11 mutations have been
reported to cause cutaneous pigmentation disorders such as
dermalmelanocytosis,(37) and studies of atopic dermatitis, which
is characterized by impaired epithelial barrier function and
eczematous skin lesions, have revealed that Gq/11-coupled
chemokine receptors facilitate the migration of inﬂammatory
cells within the dermis.(38) However, such roles of loss-of-
function Ga11 mutations in cutaneous disorders remain to be
elucidated, and these may be facilitated by studies of additional
FHH2 patients and appropriate mouse models.
Our studies have also shown that cinacalcet-mediated
allosteric modulation of the CaSR successfully rectiﬁed the
loss-of-function associated with the Phe220Ser Ga11 mutation
in vitro and in vivo. However, a higher concentration of
cinacalcet was required to normalize the signaling responses
of cells expressing the Ga11 mutant Ser220, when compared to
other FHH2-causing Ga11 mutants.
(10) These in vitro ﬁndings
suggest that loss-of-function mutations located within the
Ga11 switch regions may alter the efﬁcacy of calcimimetic
compounds, and it is notable that the hypercalcemic proband
with a Phe220Ser Ga11 mutation required an increase in the
dose of cinacalcet from 30 to 60mg daily to normalize the
elevated serum calcium concentrations (Fig. 2C). Moreover,
cinacalcet in the patient exerted an inhibitory effect on PTH
secretion, as observed by a normalization of serum PTH
concentrations. Cinacalcet may be rectifying the impaired
signaling by the mutant Phe220Ser Ga11 by increasing
signaling through the WT Ga11, which is present endogenously
in HEK293 cells and the cells of the heterozygous patient,
and/or compensatory signaling by the closely-related Gaq,
which activates the same signaling pathways downstream of
CaSR. Importantly, hypocalcemia or adverse effects such as
nausea and vomiting, which may affect >25% of patients,(39)
were not observed in the patient, despite receiving a higher
dose of cinacalcet.
In conclusion, we have identiﬁed a FHH2-causing mutation,
which affects the Ga11 switch region and disrupts PLC-mediated
signaling, and have also shown that cinacalcet can rectify these
signaling disturbances and be used successfully to treat the
hypercalcemia caused by this germline loss-of-function Ga11
mutation.
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